Reset
Showing 7 of 7 academic articles

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosisResearch in context

Matthew Lynch, Sophie Manoy, Peter D. Sly, Claire E. Wainwright et al. • EBioMedicine (2025)

Summary: Background: Ataxia-telangiectasia (A-T) is a rare multisystem disease characterised by neurodegenerative cerebellar ataxia, lung disease, immune deficiency, high cancer risk, and mitochondrial dysfunction. A-T cells demonstrate de...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.ebiom.2025.105840

Metabolic modeling-based drug repurposing in Glioblastoma

Claudio Tomi-Andrino, Alina Pandele, Klaus Winzer, John King et al. • Scientific Reports (2022)

Abstract The manifestation of intra- and inter-tumor heterogeneity hinders the development of ubiquitous cancer treatments, thus requiring a tailored therapy for each cancer type. Specifically, the reprogramming of cellular metabolism has b...

DOAJ Open Access (DOAJ) DOI: 10.1038/s41598-022-14721-w

Machine learning in pain research

Jörn Lötsch, Alfred Ultsch • Pain (2017)

1. Introduction Pain and pain chronification are incompletely understood and unresolved medical problems that continue to have a high prevalence.14 It has been accepted that pain is a complex phenomenon.2,32,72 Contemporary methods of compu...

OPENALEX cc-by-nc-nd DOI: https://doi.org/10.1097/j.pain.0000000000001118 PMC: 5895117

Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach

Kai Zhao, Yujia Shi, Hon-Cheong So • Pharmaceutics (2022)

Identification of the correct targets is a key element for successful drug development. However, there are limited approaches for predicting drug targets for specific diseases using omics data, and few have leveraged expression profiles fro...

DOAJ Open Access (DOAJ) DOI: 10.3390/pharmaceutics14020234